Table 1.
Percentage of patients pain-free at 2 hours, SPF and SNAE
| 2 hours pain-free |
SPF |
SNAE |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | RR (95% CI) | p value | N | % | RR (95% CI) | p value | N | % | RR (95% CI) | p value | |
| All patients | ||||||||||||
| Almotriptan (N = 122) | 59 | 48.4 | 1.81 (1.28–2.57) | .0008 | 44 | 36.1 | 1.99 (1.28–3.09) | .0022 | 41 | 33.6 | 1.94 (1.21–3.13) | .0061 |
| Placebo (N = 122) | 32 | 26.2 | 21 | 17.2 | 20 | 16.4 | ||||||
| Mild subgroup (post-hoc analysis) | ||||||||||||
| Almotriptan (N = 36) | 25 | 69.4 | 3.11 (1.58–6.14) | .0011 | 19 | 52.8 | 2.01 (0.93–4.36) | .0766 | 17 | 47.2 | 1.71 (0.67–4.39) | .2611 |
| Placebo (N = 32) | 7 | 21.9 | 7 | 21.9 | 7 | 21.9 | ||||||
| Moderate/severe subgroup (post-hoc analysis) | ||||||||||||
| Almotriptan (N = 86) | 34 | 39.5 | 1.42 (0.92–2.18) | .1100 | 25 | 29.1 | 1.88 (1.08–3.30) | .0268 | 24 | 27.9 | 1.95 (1.07–3.57) | .0304 |
| Placebo (N = 90) | 25 | 27.8 | 14 | 15.6 | 13 | 14.4 | ||||||
SPF = sustained pain-free (pain-free from 2–24 hours with no rescue medication). SNAE = pain-free from 2–24 hours with no rescue medication or adverse events. CI = confidence interval; RR = risk ratio.